Delivery Order SPE2DB24D1205-SPE2DB24FCRBH

Award Date 5/6/24
Potential Completion Date 5/7/24
Potential Value $5.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, is for the supply of the drug Mounjaro (generic name: tirzepatide) in a 15 mg/0.5 mL pen dosage form. The award, valued at $1,113.05, is a delivery order issued by the Defense Logistics Agency (DLA), a defense agency responsible for providing logistics and technical services to the U.S. Armed Forces. The contract is a firm-fixed price arrangement with a completion date of June 26, 2024....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of the prescription drug Mounjaro (tirzepatide) 5 mg/0.5 mL pen. The contract has a firm fixed-price, with a ceiling value of $3,818.40, and is set to expire on October 16, 2024. AmerisourceBergen, a major pharmaceutical distributor, is providing these critical medical supplies to support various Department of Defense (DoD) and federal healthcare programs. This award is likely...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the delivery of the drug Mounjaro (Tirzepatide) 5 mg/0.5 ml pen. The contract has a firm fixed price of $2,593.98 and an ultimate completion date of May 29, 2024. The award is not associated with a set-aside program. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,342.28 contract is for the supply of the drug Mounjaro (tirzepatide) 10 mg/0.5 ml pen. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product Mounjaro (tirzepatide) 7.5 mg/0.5 ml pen with a total ceiling value of $3,509.92. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of May 21, 2024. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 between Amerisourcebergen and DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,642.95, is for the procurement of the drug Mounjaro (Tirzepatide) 15 mg/0.5 ml pen. The award is not designated as a set-aside and represents a firm fixed price, delivery order under AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication Mounjaro (tirzepatide) 5 mg/0.5 ml pens. The $45,378.33 firm fixed-price contract has an ultimate completion date of October 24, 2024. AmerisourceBergen, a for-profit corporate entity registered in the System for Award Management (SAM.gov), has an extensive history of federal contract awards with DLA and other agencies,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug Mounjaro (tirzepatide) 5 mg/0.5 mL pens. The contract has a ceiling value of $20,165.02 and a period of performance through October 26, 2023. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription medication Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens. The contract has a ceiling value of $17,357.67 and an ultimate completion date of July 31, 2024. This award is placed against a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999, which...
This contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the drug Mounjaro (tirzepatide) 5 mg/0.5 ml pen. The contract, valued at $3,757.37, is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which serves as a primary vehicle for providing a...
  • SPE2DB24D1205
    Indefinite Delivery Contract
  • SPE2DB24D1205-SPE2DB24FCRBH
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen. The award, valued at $5,155.20, is a firm-fixed-price contract with a performance period ending on May 7, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth up to $999,999,999.00, which serves as the primary vehicle for the company to provide a range of pharmaceutical products and medical supplies to the Department of Defense globally. This specific award does not have a set-aside designation.

Generated 8/5/24, 9:06 AM